The following research projects led by BC Children's Hospital and BC Women's Hospital researchers are focused on investigating potential treatments for COVID-19, as well as immune responses to COVID-19 vaccines. 

Click on the study titles below for more information. 

Host Response Mediators In Coronavirus (covid-19) Infection – Is There A Protective Effect Of Losartan On Outcomes Of Coronavirus Infection?

James A. Russell, Principal Investigator

This study will address the need for effective treatments for those infected with COVID-19. Specifically, for people like you, that become ill enough to require admission to hospital, we think that an existing drug called losartan might help treat COVID-19 and hasten recovery. As such, we will investigate the safety and effectiveness of losartan in the treatment of COVID-19 and whether it can decrease the rate of death in COVID-19 patients compared to usual care of standard of care (SOC). We will also determine whether losartan can help limit damage to organs (kidney, lung, heart and liver) as this type of damage has been observed in COVID-19 patients in hospital.

CATCO: Canadian Treatments for COVID19

Srinivas Murthy, Principal Investigator

A randomized, controlled trial of lopinavir/ritonavir in hospitalized patients with confirmed COVID19.


Manish Sadarangani, Principal Investigator

Researchers at the Vaccine Evaluation Center and BC Centre for Disease Control would like to better understand immune responses to COVID-19 vaccines in adults. Multiple COVID-19 vaccines will be used in Canada and best use of these vaccines will help us control the pandemic as quickly as possible. The purpose of this study is to measure the short- and long-term immune responses generated by different COVID-19 vaccines in adults. The goals of the study are to help researchers understand immunity to COVID-19 after vaccination and to help guide policies and recommendations for how these vaccines are used.

Learn more here

CANVAS Surveillance of Adverse Events Following Immunization among Individuals Immunized with the COVID19 Vaccine

Julie Bettinger, Principal Investigator

The Canadian National Vaccine Safety (CANVAS) Network is a national platform that monitors vaccine safety after vaccines are approved for use. We are monitoring the safety of the COVID-19 vaccines in Canada and we need YOUR help.

Using a web-based survey we will collect information about whether or not health events occur after receiving COVID-19 vaccines. We will also collect health events from people who have not received a COVID-19 vaccine.

Learn more here

Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network

Manish Sadarangani, Principal Investigator

The overall purpose of this study is to inform the development of a standardized approach to clinical care of patients who have had a medically significant AEFI after COVID-19 vaccination.

Systematic assessment and follow up of patients with medically significant adverse events following COVID-19 vaccines is needed to describe the types of events that come to medical attention, their severity/seriousness and the patient populations affected, to ensure patients who develop AEFIs receive the care they need, and to support public health safety surveillance and rapid evaluation of emerging vaccine safety signals.

COVID-19 Ring-based Prevention trial with Lopinavir/ritonavir (CORIPREV LR)

Natasha Press, Principal Investigator

The purpose of this study is to evaluate the efficacy of a 14-day course of oral lopinavir/ritonavir (LPV/r) as PEP against microbiologically confirmed COVID-19 among individuals with a significant unprotected exposure to a confirmed case.

Prevention interventions are critical for the trial’s key target populations: frail elderly in congregate living or health care facilities; health care workers; and household/community contacts of confirmed COVID-19 cases. Breaking chains of spread in nursing/retirement/long-term care homes, among healthcare workers, and in the community will be vital to limiting the impact of this disease.

Best Available Treatment Study for the Paediatric Inflammatory Multisystem Inflammatory Syndrome

Catherine Biggs, Principal Investigtor

There are reports from throughout the world of children presenting with fever and other signs of inflammation in the setting of the COVID-19 pandemic. This newly identified syndrome is referred to as multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19.
While randomized trials are needed to determine optimal MIS-C treatment, they will take time to establish. The proposed "best available treatment study" is an international initiative aimed at rapidly evaluating the current treatments being employed by clinicians to treat patients with MIS-C. The aims are: determine which patients to treat, which treatments work, and which may be harmful.